Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)

DRUG2 trials

Sponsors

NYU Langone Health, University of California, San Francisco

Conditions

FentanylOpioid DependenceOpioid Use Disorder

Phase 4

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

CompletedNCT03604159

NYU Langone HealthOpioid Dependence

Start: 2019-06-24End: 2020-05-04Updated: 2022-01-11

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

Not yet recruitingNCT07469501

University of California, San FranciscoFentanyl, Opioid Use Disorder

Start: 2026-06-01End: 2027-05-01Target: 50Updated: 2026-03-13

Related Papers

Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.

2022-01-2919 citations

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail

JAMA Network Open2021-09-0863 citations